Which oxygen saturation level should we use for very premature infants? A randomised controlled trial
| ISRCTN | ISRCTN00842661 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN00842661 |
| Protocol serial number | G0400415 |
| Sponsor | University of Oxford (UK) |
| Funder | Medical Research Council (UK) |
- Submission date
- 07/02/2006
- Registration date
- 23/03/2006
- Last edited
- 08/03/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Neonatal Diseases
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
NPEU
University of Oxford
Old Road Campus
Oxford
OX3 7LF
United Kingdom
| Phone | +44 (0)1865 289719 |
|---|---|
| Peter.Brocklehurst@npeu.ox.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Double-blind randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Which oxygen saturation level should we use for very premature infants? A randomised controlled trial |
| Study acronym | BOOST-II UK |
| Study objectives | Does varying the concentration of inspired oxygen so as to target a low (85-89%) versus a high (91-95%) functional arterial oxygen saturation (SpO2), from the day of birth until the baby is breathing air (or until the baby has reached a postmenstrual age of at least 36 weeks) affect the incidence of: 1. Retinopathy of prematurity (plus disease or Grade 3 and 4) and its two year outcome? 2. Other surgery (for conditions such as patent ductus arteriosus, post-haemorrhagic ventriculomegaly or necrotising enterocolitis)? 3. Chronic lung disease? 4. Death or severe neurosensory disability on assessment 2 years after the child was due to be born? 5. Poor weight gain and head growth between birth and 36 weeks postmenstrual age, and between birth and 2 years of age? |
| Ethics approval(s) | Trent Multi-Centre Ethics Committee, 02/05/2007, ref: 06/MRE04/91 |
| Health condition(s) or problem(s) studied | Prematurity |
| Intervention | The intervention is to maintain functional oxygen saturations in the range 85-89% or 91-95%. Masimo radical oximeters (Irvine, CA) will be used to monitor oxygen saturation levels. The oximeters will be modified to display and store a figure that is either 3% above or 3% below the 'true' oxygen saturation between 85% and 95% as computed by the machines' internal algorithm. Outside of these limits the oximeter will display the true value. Staff will aim for an oximeter reading of between 88 and 92%. This will, therefore, generate two trial groups: one for which oxygen saturation is maintained at 85-89%, and one for which it is maintained at 91-95%. Added 30/11/2015: The Masimo oximeters used in the trial were revised on 08/12/2008 to correct an artefact in their calibration algorithm. Achieved oxygen saturation distributions were clearly different with the revised oximeters. On 02/11/2009 the Data Monitoring Committee recommended that the Trial Steering Committee should consider whether the data from the two oximeter types should be considered separately. On 01/12/2010, blind to any outcome data, the Trial Steering Committee recommended to the Chief Investigator to change the protocol and to enrol the originally intended target sample size of 1,200 infants using the revised oximeters and to make this the primary analysis outcome population for the trial. A secondary analysis was planned to include the results of the infants treated with the original oximeters. |
| Intervention type | Other |
| Primary outcome measure(s) |
Death or serious neurosensory disability at 2 years corrected for prematurity |
| Key secondary outcome measure(s) |
1. Respiratory outcomes: |
| Completion date | 31/05/2014 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Neonate |
| Sex | All |
| Target sample size at registration | 973 |
| Key inclusion criteria | Infants are eligible if they are: 1. Less than 28 weeks gestation at birth 2. Less than 12 h old (24 h if the baby is outborn) 3. The clinician and parents are substantially uncertain which SpO2 is better |
| Key exclusion criteria | Recruitment is not appropriate if there is no realistic prospect of survival, or follow-up is unlikely to be possible |
| Date of first enrolment | 29/09/2007 |
| Date of final enrolment | 24/12/2010 |
Locations
Countries of recruitment
- United Kingdom
- England
- Ireland
Study participating centre
OX3 7LF
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 30/05/2013 | Yes | No | |
| Results article | results | 25/02/2016 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
08/03/2016: Publication reference added.
On 02/12/2013 the overall trial end date was changed from 30/11/2013 to 31/05/2014.
On 06/12/2012 Ireland was added to the countries of recruitment.